Surveillance of antimicrobial susceptibility patterns among Stenotrophomonas maltophilia isolated in China during the 10-year period of 2005–2014

References

• Nyč O, Matějková J. Stenotrophomonas maltophilia: significant contemporary hospital pathogen-review. Folia Microbiol (Praha). 2010;55:286–94.
   PubMed Web of Science ®Google Scholar
• Wang CH, Lin JC, Lin HA, Chang FY, Wang NC, Chiu SK, et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study. J Microbiol Immunol Infect. 2014;14:1–9.
   Google Scholar
• Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther. 2011;9:471–88.10.1586/eri.11.24
   PubMed Web of Science ®Google Scholar
• Kierzkowska M, Majewska A, Dobrzaniecka K, Sawicka-Grzelak A, Mlynarczyk A, Chmura A, et al. Blood infections in patients treated at transplantation wards of a clinical hospital in Warsaw. Transplant Proc. 2014;46:2589–91.10.1016/j.transproceed.2014.08.024
   PubMed Web of Science ®Google Scholar
• Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect. 2008;70:101–8.10.1016/j.jhin.2008.05.020
   PubMed Web of Science ®Google Scholar
• Alonso A, Sanchez P, Martinez JL. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob Agents Chemother. 2000;44:1778–82.10.1128/AAC.44.7.1778-1782.2000
   PubMed Web of Science ®Google Scholar
• Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother. 2000;44:287–93.10.1128/AAC.44.2.287-293.2000
   PubMed Web of Science ®Google Scholar
• Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol. 2008;9:R74.10.1186/gb-2008-9-4-r74
   PubMed Web of Science ®Google Scholar
• Barbolla R, Catalano M, Orman BE, Famiglietti A, Vay C, Smayevsky J, et al. Pineiro. Class 1 integrons increases trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2004;48:666–9.10.1128/AAC.48.2.666-669.2004
   PubMed Web of Science ®Google Scholar
• Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al. Stenotrophomonas maltophilia resistance to trimethoprim/ sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class 1 integron. Int J Antimicrob Agents. 2011;37:230–4.10.1016/j.ijantimicag.2010.10.025
   PubMed Web of Science ®Google Scholar
• Song JH, Sung JY, Kwon KC, Park JW, Cho HH, Shin SY, et al. Analysis of acquired resistance genes in Stenotrophomonas maltophilia. Korean J Lab Med. 2010;30:295–300.10.3343/kjlm.2010.30.3.295
   PubMedGoogle Scholar
• Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98:1836–47.10.3324/haematol.2013.091330
   PubMed Web of Science ®Google Scholar
• CS Lee, Y Doi. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother. 2014; 46: 149-64.10.3947/ic.2014.46.3.149
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-third informational supplement, M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
   Google Scholar
• Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients. Geographic patterns, epidemiological features and trends in SENTRY antimicrobial surveillance program (1997–1999). Clin Infect Dis. 2001;32:104–13.10.1086/cid.2001.32.issue-s2
   PubMed Web of Science ®Google Scholar
• Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect. 2004;57:1–7.10.1016/j.jhin.2004.01.033
   PubMed Web of Science ®Google Scholar
• Bonatti H, Pruett TL, Brandacher G, Hagspiel KD, Housseini AM, Sifri CD, et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc. 2009;41:371–4.10.1016/j.transproceed.2008.10.045
   PubMed Web of Science ®Google Scholar
• Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci. 2013;28:62–6.10.3346/jkms.2013.28.1.62
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 2010;54:2735–7.10.1128/AAC.01774-09
   PubMed Web of Science ®Google Scholar
• Wu H, Wang JT, Shiau YR, Wang HY, Yang Lauderdale TL, Chang SC. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect. 2012;45:120–6.10.1016/j.jmii.2011.09.028
   PubMedGoogle Scholar
• Cho SY, Lee DG, Choi SM, Park C, Chun HS, Park YJ, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis. 2015;19:56.
   Google Scholar
• George S, Karageorgopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasilis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility, and treatment outcome. PLoS ONE. 2012;7:e37375.
   PubMed Web of Science ®Google Scholar
• Kaur P, Gautam V, Tewari R. Distribution of class 1 integrons, sul1 and sul2 genes among clinical isolates of Stenotrophomonas maltophilia from a tertiary care hospital in North India. Microb Drug Resist. 2015;21:380–5.10.1089/mdr.2014.0176
   PubMed Web of Science ®Google Scholar
• Sun AM, Wang YQ, Wang W. Detection rate of Stenotrophomonas maltophilia and the drug resistance analysis. China J Nosocomiol. 2015;25:5317–9.
   Google Scholar
• Wang DF, Lou N. Risk factors for pulmonary infections caused by Stenotrophomanas maltophilia in severe tumor patients. China J Nosocomiol. 2014;24:1394–6.
   Google Scholar
• Zhao S, Yang L, Liu H, Gao F. Stenotrophomonas maltophilia in a university hospital of traditional Chinese medicine: molecular epidemiology and antimicrobial resistance. J Hosp Infect. 2017;96:286–9.10.1016/j.jhin.2017.04.001
   PubMed Web of Science ®Google Scholar
• Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 2015;6:893.
   PubMed Web of Science ®Google Scholar
• Al-Anazi AA, Al-Jasser AM. Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:232.
   PubMedGoogle Scholar
• Church D, Lloyd T, Peirano G, Pitout J. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis. 2013;45:265–70.10.3109/00365548.2012.732240
   PubMed Web of Science ®Google Scholar
• Guo W, He Q, Wang Z, Wei M, Yang Z, Du Y, et al. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008–2013 at a tertiary hospital in Shanghai. China. Am J Infect Control. 2015;43:358–64.10.1016/j.ajic.2014.12.010
   PubMed Web of Science ®Google Scholar
• Korytny A, Riesenberg K, Saidel-Odes L, Schlaeffer F, Borer A. Bloodstream infections caused by multi-drug resistant Proteus mirabilis: Epidemiology, risk factors and impact of multi-drug resistance. Infect Dis (Lond). 2016;14:1–4.
   Google Scholar
• Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother. 2008;62:889–94.10.1093/jac/dkn301
   PubMed Web of Science ®Google Scholar